Form 4: Edwards Lifesciences CFO Executes Stock Option Exercise
Statement of Changes in Beneficial Ownership
CFO Scott B. Ullem exercised 13,000 stock options and conducted related tax withholding transactions in early May 2026.
Summary
- Scott B. Ullem, CVP and CFO of Edwards Lifesciences, exercised 13,000 employee stock options at a price of $59.2567 per share on May 5, 2026.
- The reporting person disposed of 620 shares on May 3, 2026, and 11,131 shares on May 5, 2026, to satisfy tax withholding obligations related to equity awards.
- Following these transactions, the reporting person holds 40,948 shares directly and 266,318 shares indirectly through a trust.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the transactions are routine administrative actions related to executive compensation and tax obligations.
Positives
- The exercise of options indicates continued alignment between executive interests and long-term shareholder value.
Negatives
- The transaction involved the immediate sale of a significant portion of the acquired shares to cover tax liabilities, which is standard but reduces net share accumulation.
Risks
- Market volatility affecting the value of remaining direct and indirect holdings.
Future Outlook
No specific forward-looking guidance provided in this regulatory filing.
Industry Context
StockSavvy.ai notes that routine Form 4 filings regarding tax-related share dispositions are standard practice for corporate executives and generally do not signal a change in strategic outlook or confidence in the company.
Comparison to Industry Standards
- The transaction follows standard corporate governance practices for executive compensation and tax management.
- The volume of shares traded is consistent with typical executive equity management patterns for large-cap medical device companies.
Stakeholder Impact
- Minimal impact on shareholders as the transactions represent standard executive compensation management.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 05/03/2026 | Transaction date for tax withholding disposition of 620 shares. |
| 05/05/2026 | Transaction date for option exercise and subsequent tax withholding disposition. |
Keywords
Edwards Lifesciences, EW, Insider Trading, Form 4, CFO, Stock Options
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.